TABLE 2.
SARS-CoV-2 neutralization assay platforms used in the study
| SARS-CoV-2/VeroE6 | VSV-pseudo/Vero | LV-pseudo/293T | LV-pseudo/TZM-bl | HTS-LV-pseudo/293T | Surrogate virus neutralization test (sVNT) | |
|---|---|---|---|---|---|---|
| Lab | Baric | Corey | Montefiori | Montefiori | Huang/Jerome | Corey |
| Cell line | Vero E6 | Vero | HEK293T | TZM-bl | HEK293T | None |
| ACE2 expression | Endogenous | Endogenous | Engineered | Engineered | Engineered | Recombinant |
| TMPRSS2 expression | No | No | No | Engineered | No | NAa |
| Virus shorthand | rSARS-CoV-2-nLuc | VSV-pseudo | LV-pseudo | LV-pseudo | HTS-LV-pseudo | NA |
| Virus type | Live recombinant | VSV(G*ΔG-luciferase) pseudotyped | pCMV-ΔR8.2 lentiviral packaging with pHR'-CMV-Luc | pSG3ΔEnv lentiviral packaging | pHDM lentiviral packaging | NA |
| SARS-CoV-2 strain/isolate | WA-CDC-WA1-A12/2020 | Wuhan-Hu-1 | Wuhan-Hu-1 (VRC7480) D614G | Wuhan-Hu-1 (VRC7480) D614G | Wuhan-Hu-1 D614G | Unknown |
| GenBank | MT020880.1 | MN908947.3 | MN908947.3 | MN908947.3 | MN908947.3 | NA |
| Amino acid 614 | D | D | G | G | G | Unknown |
| Biosafety level | 3 | 2 | 2 | 2 | 2 | 1 |
a
NA, not available.